Teriparatide transdermal - Corium International

Drug Profile

Teriparatide transdermal - Corium International

Alternative Names: hPTH(1-34) - Corium International; Human PTH(1-34) - Corium International; MicroCor PTH; Parathyroid hormone (1-34) - Corium International; Parathyroid hormone transdermal - Corium International; PTH (1-34) - Corium International

Latest Information Update: 06 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Corium International
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Osteoporosis

Most Recent Events

  • 06 Sep 2017 Teriparatide is still undergoing phase-II clinical trials in Osteoporosis (In adults, In elderly) in Australia (Transdermal)
  • 28 Jul 2015 Interim pharmacokinetics, pharmacodynamics and adverse events data from a phase IIa trial in Osteoporosis (In adults, In elderly) released by Corium International
  • 01 Feb 2015 Phase-II clinical trials in Osteoporosis (In adults, In elderly) in Australia (Transdermal) (ACTRN12615000195550)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top